The latter comprised FDA approved TNF-alpha antagonists (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol) that were found to be associated with lower Alzheimer’s disease risk in patients with rheumatoid arthritis and psoriasis (Zhou et al., 2020) and proved positive immune and cognitive outcomes in rodent models of Alzheimer’s disease (Kim et al., 2016; Paouri et al., 2017; Park et al., 2019). This evidence concerns the gene TNF and early-onset autosomal dominant Alzheimer disease.